[HTML][HTML] Skin problems and EGFR-tyrosine kinase inhibitor
T Kozuki - Japanese journal of clinical oncology, 2016 - ncbi.nlm.nih.gov
Epidermal growth factor receptor inhibition is a good target for the treatment of lung, colon,
pancreatic and head and neck cancers. Epidermal growth factor receptor-tyrosine kinase …
pancreatic and head and neck cancers. Epidermal growth factor receptor-tyrosine kinase …
[HTML][HTML] First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III …
Background The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer
LT Huang, SL Zhang, CB Han, JT Ma - Lung Cancer, 2022 - Elsevier
Abstract Objective Exon 19 deletion (19del) is a sensitive mutation of epidermal growth
factor receptor (EGFR) observed in non-small cell lung cancer (NSCLC), and consists of a …
factor receptor (EGFR) observed in non-small cell lung cancer (NSCLC), and consists of a …
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
H Akamatsu, K Ninomiya, H Kenmotsu… - International journal of …, 2019 - Springer
According to rapid development of chemotherapy in advanced non-small cell lung cancer
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually …
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually …
Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced …
Y Zhang, J Sheng, S Kang, W Fang, Y Yan, Z Hu… - PloS one, 2014 - journals.plos.org
Backgrounds It has been extensively proved that the efficacy of epidermal growth factor
receptor-tyrosine kinase inhibitors (EGFR-TKIs) is superior to that of cytotoxic chemotherapy …
receptor-tyrosine kinase inhibitors (EGFR-TKIs) is superior to that of cytotoxic chemotherapy …
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
M Takeda, I Okamoto, K Nakagawa - Lung Cancer, 2015 - Elsevier
Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of …
T Kato, H Yoshioka, I Okamoto, A Yokoyama… - Cancer …, 2015 - Wiley Online Library
In LUX‐Lung 3, afatinib significantly improved progression‐free survival (PFS) versus
cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall …
cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall …
Concurrent EGFR‐TKI and thoracic radiotherapy as first‐line treatment for stage IV non‐small cell lung cancer harboring EGFR active mutations
LP Zheng, Y Wang, Z Xu, Q Yang, G Zhu… - The …, 2019 - academic.oup.com
Abstract Lessons Learned This single‐arm, phase II study shows that concurrent EGFR‐
tyrosine kinase inhibitor plus thoracic radiotherapy as the first‐line treatment for stage IV non …
tyrosine kinase inhibitor plus thoracic radiotherapy as the first‐line treatment for stage IV non …
[HTML][HTML] Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M–positive NSCLC Treated …
A Gemma, M Kusumoto, F Sakai, M Endo, T Kato… - Journal of Thoracic …, 2020 - Elsevier
Abstract Introduction Using real-world Japanese postmarketing data, we characterized
interstitial lung disease (ILD) development during the second-or later-line osimertinib …
interstitial lung disease (ILD) development during the second-or later-line osimertinib …
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta …
Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …